Shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) were up 5.2% during trading on Monday . The company traded as high as $18.79 and last traded at $18.70. Approximately 1,322,000 shares changed hands during mid-day trading, a decline of 32% from the average daily volume of 1,950,505 shares. The stock had previously closed at $17.77.

A number of analysts have recently commented on ARWR shares. Cantor Fitzgerald restated a “buy” rating and issued a $13.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, May 30th. BidaskClub upgraded Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 2nd. S&P Equity Research cut their price objective on Arrowhead Pharmaceuticals from $13.76 to $11.68 in a research report on Monday, June 18th. Piper Jaffray Companies restated an “overweight” rating and issued a $17.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Friday, June 29th. Finally, Chardan Capital boosted their price objective on Arrowhead Pharmaceuticals from $9.50 to $16.00 and gave the company a “buy” rating in a research report on Monday, July 2nd. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $19.03.

The company has a debt-to-equity ratio of 0.02, a current ratio of 8.69 and a quick ratio of 8.69. The company has a market capitalization of $1.65 billion, a PE ratio of -41.21 and a beta of 1.91.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.01. The firm had revenue of $0.73 million for the quarter, compared to analyst estimates of $0.62 million. Arrowhead Pharmaceuticals had a negative return on equity of 59.39% and a negative net margin of 400.13%. research analysts predict that Arrowhead Pharmaceuticals Inc will post -0.64 EPS for the current fiscal year.

In other news, CEO Christopher Richard Anzalone sold 100,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, August 31st. The stock was sold at an average price of $14.45, for a total value of $1,445,000.00. Following the sale, the chief executive officer now directly owns 1,868,789 shares of the company’s stock, valued at $27,004,001.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kenneth Allen Myszkowski sold 45,000 shares of the business’s stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $19.34, for a total value of $870,300.00. Following the transaction, the chief financial officer now directly owns 335,815 shares in the company, valued at approximately $6,494,662.10. The disclosure for this sale can be found here. Insiders sold 309,834 shares of company stock worth $4,697,151 over the last ninety days. Corporate insiders own 4.60% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Arrowhead Pharmaceuticals during the second quarter worth $100,000. Great West Life Assurance Co. Can acquired a new position in Arrowhead Pharmaceuticals during the second quarter worth $106,000. Trexquant Investment LP acquired a new position in Arrowhead Pharmaceuticals during the first quarter worth $139,000. Macquarie Group Ltd. acquired a new position in Arrowhead Pharmaceuticals during the second quarter worth $151,000. Finally, Amalgamated Bank acquired a new position in Arrowhead Pharmaceuticals during the second quarter worth $181,000. 58.77% of the stock is currently owned by institutional investors.

About Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Recommended Story: How Do Tariffs Affect Trade Balances?

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.